Evidence map›Paper›PMID 33368640›Full record

ArticleJournal of clinical laboratory analysis2021

Decreased serum exosomal miR-29a expression and its clinical significance in papillary thyroid carcinoma.

Qiuting Wen, Yulou Wang, Xingjiang Li, Xiangguo Jin, Guimei Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical laboratory analysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 3 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. CTC, ctDNA, and Exosome in Thyroid Cancers: A Review.International journal of molecular sciences · 2023
    Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Qiuting WenDepartment of Pathology, Qiqihar Medical University, Qiqihar, China.
Yulou WangDepartment of General Surgery, The First Affiliated Hospital of Qiqihar Medical University, Qiqihar, China.ORCID https://orcid.org/0000-0003-4386-7192
Xingjiang LiDepartment of General Surgery, The First Affiliated Hospital of Qiqihar Medical University, Qiqihar, China.
Xiangguo JinDepartment of General Surgery, The First Affiliated Hospital of Qiqihar Medical University, Qiqihar, China.
Guimei WangDepartment of General Surgery, The First Affiliated Hospital of Qiqihar Medical University, Qiqihar, China.
Qiqihar Medical University · CN

Funding

Basic Research Project of Basic Scientific Research and Business Fee of Heilongjiang Provincial Education Department 2017-QYKYYWF-0756
6 · The paper itself

Abstract

backgroundAberrant levels of circulating microRNAs (miRNAs) are potential biomarkers in papillary thyroid carcinoma (PTC) diagnosis and therapy. The aim of this study was to evaluate serum exosomal miR-29a expression as a non-invasive biomarker for PTC diagnosis and prognosis.

methodsQuantitative reverse transcription polymerase chain reaction was applied to measure serum exosomal miR-29a expression levels in blood samples of 119 patients with PTC and 100 control subjects.

resultsSerum exosomal miR-29a expression levels were significantly decreased in PTC cases. In addition, receiver operating characteristic (ROC) analysis revealed serum exosomal miR-29a could well differentiate PTC from normal controls. Moreover, serum exosomal miR-29a levels increased progressively and significantly 30 days and 90 days after surgery. Furthermore, PTC patients with lower serum exosomal miR-29a expression had higher risk of recurrence. Decreased serum exosomal miR-29a expression was significantly associated with worse clinical variables including tumor size, extrathyroidal extension, and TNM stage, as well as shorter survival. Finally, both univariate and multivariate identified serum exosomal miR-29a as an independent prognostic indicator for overall survival.

conclusionThese results demonstrated that serum exosomal miR-29a might serve as a potential biomarker for PTC diagnosis and prognosis.

Indexed as

Thyroid Cancer, PapillaryThyroid NeoplasmsBiomarkers, TumorExosomesFemaleHumansMaleMicroRNAsMiddle AgedPrognosisBiomarkers, TumorMicroRNAsMIRN29a microRNA, humanbiomarkermiR-29apapillary thyroid carcinomaserum exosomes

Identifiers

PMID33368640
PMCPMC7843262
OpenAlexW3116460360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.